Q3 2022

Filed Nov 3, 2022 · 10-Q · 34 days after period end · 0000950170-22-021848

Q3 2022 · 10-Q

Revenue—

Net Income

-$35.40M

N/M vs Q3 2021

EPS Diluted

-$0.58

N/M vs Q3 2021

Operating Income-$35,141,000N/M

Operating Cash Flowderived-$28,544,000N/M

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	—	$12.38M	$379.00K	$379.00K
Net Income	-$35.40M	-$20.64M	-$20.44M	-$12.83M
EPS Diluted	-$0.58	-$0.40	-$0.46	-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR